Injury Care Solutions Group pitches expert support for Depo-Provera meningioma litigation

Injury Care Solutions Group is positioning itself as a source of expert support for attorneys handling Depo-Provera meningioma cases as multidistrict litigation moves forward in federal court. The company says its services are aimed at helping lawyers build claims beyond the MDL record, with a focus on medical, regulatory and life care evidence.

Why it matters: - Depo-Provera meningioma litigation is moving through federal multidistrict proceedings in the Northern District of Florida. - Attorneys handling the cases may need expert support beyond the MDL work product as discovery and Daubert rulings continue. - The litigation centers on whether Depo-Provera is linked to cerebral meningiomas and how that scientific record will hold up in court.

What happened: - Injury Care Solutions Group said it provides expert services for attorneys prosecuting Depo-Provera meningioma cases. - Greg Vigna, MD, JD, a board-certified PM&R physician and life care planner, said the firm offers expert solutions for litigating attorneys. - Vigna said the company can help lawyers pursue claims beyond the work product generated in the MDL. - Vigna said uncertainty remains about how expert opinions used in the MDL will fare because some attorneys who understood the basis for those opinions settled their dockets before the court issued Daubert decisions and before discovery concluded on issues including Pfizer’s handling of adverse events.

The details: - Injury Care Solutions Group says it provides physician life care planning services. - The company says its expert network includes epidemiologists, neurosurgeons, neuropathologists, regulatory and clinical testing experts, life care planners and others. - Vigna said the peer-reviewed literature has foreclosed causation questions and that Depo-Provera causes cerebral meningiomas by inducing tumorigenesis of normal meningeal tissue into diagnosable meningiomas. - Vigna said the mechanism may involve growth of pre-existing meningiomas or expansion of cellular clones with mutations consistent with meningioma within normal meninges. - Vigna pointed readers to Matthieu Peyre, MD, PhD’s article, “Progestin-associated meningiomas,” in Neurosurgical Focus 61(3):E2, 2026: Read the article. - Peyre wrote that progestogens may promote growth of pre-existing meningiomas through volumetric nonproliferative mechanisms or localized expansion of cellular clones. - Peyre said the hypothesis is consistent with mutations tied to meningeal tumorigenesis being found in histologically normal meninges in up to 80% of cases. - The Depo-Provera products liability case is pending in U.S. District Court for the Northern District of Florida, Pensacola Division, under case No. 3:25-md-3140 before Judge M. Casey Rodgers and Magistrate Judge Hope T. Cannon.

Between the lines: - The company is not just advertising services; it is making a litigation strategy argument about scientific proof and expert durability. - The messaging suggests defense and plaintiff teams may continue fighting over causation, expert methodology and the scope of discovery. - By citing published research, Injury Care Solutions Group is trying to anchor its litigation pitch in the broader medical literature rather than only in the MDL record.

What's next: - Expert disputes, discovery fights and Daubert challenges are likely to remain central as the MDL advances. - Attorneys pursuing these cases may look for outside experts to support causation, regulatory and damages theories. - The court record will continue to shape how much weight experts can assign to Depo-Provera’s role in meningioma claims.

The bottom line: - Injury Care Solutions Group is selling expert support for a high-stakes drug litigation that still hinges on science, causation and courtroom admissibility.